Patients who received the mTOR inhibitor everolimus were more likely to be cancer-free a year after therapy than those who took a placebo drug, and the benefit persisted for those with mutations in their TP53 gene.
from Medindia Health News https://ift.tt/32CppFM
No comments:
Post a Comment